Sort
48,018 grants matching “immunotherapy”
Mouse models of Kras-mutant colorectal cancer
$626,771Kevin Michael Haigis · Dana-Farber Cancer Inst · R01 · FY2023 · CA
Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)
$626,768James R. Heath · California Institute Of Technology · R01 · FY2015 · CA
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer
$626,640Leopoldo Nicolas Segal · New York University School Of Medicine · R37 · FY2023 · CA
Dissecting the Mechanism for Transient ER Stress-Induced Anti-Tumor T Cell Response
$626,534Shikhar Mehrotra · Medical University Of South Carolina · R01 · FY2025 · CA
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
$626,526Daniel J. Powell · University Of Pennsylvania · R01 · FY2024 · CA
Project 3: Integrative approach tounderstanding the mechanism ofcostimulation
$626,414Arlene H Sharpe · Yale University · P01 · FY2018 · AI
Oral microbiome and inflammatory status in antimicrobially-treated oral cancer patients
$626,400Yvonne L Kapila · University Of California Los Angeles · R01 · FY2025 · CA
"TARGETING B7X AND B7-H3 AND NEW IMMUNOTHERAPIES FOR PROSTATE CANCER"
$626,250Albert Einstein College Of Medicine · · FY2014 · Department of Defense
Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer
$626,197Andrew T Chan · Massachusetts General Hospital · R01 · FY2021 · CA
Cancer Vaccines and Modulation of Checkpoint Controls in Immunization
$626,094John Janik · Basic Sciences · Z01 · FY2007 · CA
Vectorized scFv antibodies to treat tau pathology in Alzheimer's disease: enhancing epitope targeting and delivery strategies
$626,060Cristina D'abramo · Feinstein Institute For Medical Research · R01 · FY2024 · AG
Advanced Imaging Tools to Assess Cancer Therapeutics in Pediatric
$626,039Heike Elizabeth Daldrup-Link · Stanford University · R01 · FY2023 · CA
Immunotherapy of low grade lymphoid malignancies
$626,036Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2015 · HL
Epigenomic Mechanisms & Contextual Immunity in Persistent MRSA Bacteremia
$626,031Michael R Yeaman · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · U19 · FY2024 · AI
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer
$625,866Maximilian Diehn · Stanford University · R01 · FY2020 · CA
Translation of a novel combination therapy approach for non-Hodgkin lymphoma
$625,851Shruthi Naik · Mayo Clinic Rochester · U01 · FY2023 · CA
Advanced Imaging Tools to Assess Cancer Therapeutics in Pediatric
$625,750Heike Elizabeth Daldrup-Link · Stanford University · R01 · FY2025 · CA
Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma
$625,681Sandra P D'angelo · Sloan-Kettering Inst Can Research · R01 · FY2025 · FD
Integrating Epigenetic Modulation into DNA Damage Repair
$625,664Pamela N Munster · University Of California, San Francisco · R01 · FY2024 · CA
Decoding tobacco-related oral cancer ecosystem by integrative approach
$625,660Aik Choon Tan · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · DE
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck
$625,507Dong Moon Shin · Emory University · R01 · FY2023 · CA
Naive T cells in Cancer Immune Evasion and Immunotherapy
$625,446Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2018 · CA
Type 2 immunity: a primitive response to epithelial injury that shapes bone marrow and lung myeloid crosstalk
$625,412Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
Molecular epidemiology of non-Hodgkin lymphoma prognosis and prevention
$625,398Sophia S. Wang · Beckman Research Institute/City Of Hope · R01 · FY2013 · CA
Personalized Immunotherapy of Patients with Ovarian Cancer
$625,397Paul J Sabbatini · Sloan-Kettering Inst Can Research · P01 · FY2017 · CA